Cat # changed from REA203/96 to EA214/96
											 
												Type
 
											Competitive ELISA, Immobilized antigen
												Description
 
											The competitive SDMA human ELISA uses the microtiter plate format. SDMA is
bound to the solid phase of the microtiter plate. SDMA in the samples is
acylated and competes with solid phase bound SDMA for a fixed number of
rabbit anti-SDMA antiserum binding sites. When the system is in equilibrium,
free antigen and free antigen-antiserum complexes are removed by washing.
The antibody bound to the solid phase SDMA is detected by anti-rabbit /
peroxidase. The substrate TMB / peroxidase reaction is monitored at 450 nm.
The amount of antibody bound to the solid phase SDMA is inversely
proportional to the SDMA concentration of the sample.
												Applications
 
											Serum, Plasma-EDTA
												Sample Requirements
 
											20 μl/well
												Shipping
 
											At ambient temperature. Upon receipt, store the product at the temperature recommended below.
												Storage/Expiration
 
											Store the complete kit at 2–8°C. Under these conditions, the kit is stable until the expiration date (see label on the box).
												Calibration Range
 
											0–3.0 µmol/l
												Limit of Detection
 
											0.03 μmol/l
												Spiking Recovery
 
											97%(EDTA-plasma), 93% (serum)
												Dilution Linearity
 
											97% (EDTA-plasma)
												Note
 
											The kits are CE-IVD certified and intended for professional use.
								
							 
							
								
												Features
 
											
- For in vitro diagnostic use only
- standards 1-6: 0-3.0 µmol/l (0-606 ng/ml)
- limit of detection 0.03 μmol/l
- Material of animal origin used in the preparation of the kit has been obtained from animals certified as healthy but these materials should be handled as potentially infectious.
Research topic
 
											Renal disease
												Summary
 
											Dosing of most drugs must be adapted in renal insufficiency, making accurate
assessment of renal function an essential component of diagnostics in clinical
medicine. Furthermore, even modest impairment of renal function has been
recognized as a cardiovascular risk factor. As the most commonly used marker
of renal excretory function, serum creatinine concentration, does not
adequately respond to mild to moderate impairment of renal function, more
sensitive markers for renal excretory function are urgently seeked, especially
in mild stages of renal impairment. SDMA is a methylated derivative of the
amino acid L-arginine (symmetric dimethylarginine). SDMA is eliminated from
the body exclusively by renal excretion; therefore SDMA plasma
concentration is tightly related to renal function. Thus, quantification of
plasma SDMA is an adequate means to assess renal function, as could be
demonstrated in a series of recent clinical trials: In 18 clinical studies involving
more than 2,100 patients systemic SDMA concentrations were highly
correlated with inulin clearance as well as with various clearance estimates
and better corresponded to mild renal function impairment than serum
creatinine.
Thus, SDMA exhibits properties of a reliable marker of renal function.
Furthermore, there is evidence showing that elevated SDMA levels, as they
may occur in renal function impairment, may prospectively indicate future risk
of cardiovascular disease and mortality independently of the level of renal
impairment.
								
							 
							
	
				Find documents for the lot
				
				
						
						Example Instructions for Use (RUO)
						
					
							Example Instructions for Use (RUO)
							
						
					
						
						Safety Information (RUO)
						
					
							MSDS (RUO)
							
						
					
						
						Product Brochure
						
					
							CE IVD Assays
							
						
					
						
						Other Documents
						
					
							Declaration of Conformity